القائمة

Jiangsu GMP Certificate No. 278: API Scope and Limits

Jiangsu GMP Certificate No. 278: API Scope and Limits

المؤلف: HTNXT-Thomas Caldwell-Health & Medicine وقت الإصدار: 2026-11-17 04:19:09 تحقق الأرقام: 17
OSD manufacturing area used as an industry scene for pharmaceutical API and formulation supply
OSD manufacturing area at Changzhou Ruiming Pharmaceutical Co., Ltd., shown as an industry scene for API and formulation supply.

Jiangsu GMP Certificate No. 278 is not a portfolio-wide clearance. It is a Chinese GMP compliance inspection notice with a defined product and site scope. In the supplied record, the certificate lists Amlodipine Besylate API, Felodipine API, Propafenone HCl API, Levamlodipine Besylate API and Methoxyphenamine HCl API, and it applies to the CN, EU and other markets. For an EU-bound buyer, the document is useful only when its product list, manufacturing-line references and market role are matched to the right API and the right accompanying quality document.

The certificate is held in the supplied record by Changzhou Ruiming Pharmaceutical Co., Ltd., a Jiangsu-based pharmaceutical company founded in 2005 and located at No.1558 Longjiang North Road, Chunjiang Town, Xinbei District, Changzhou City, Jiangsu Province. Its stated activities cover R&D, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients and preparations related to cardiovascular, urinary, respiratory and digestive systems. That company context matters because Certificate No. 278 is a site-and-product scope document, not a batch release record.

What Certificate No. 278 actually is

The document’s formal title is Notice of GMP Compliance Inspection for Pharmaceutical Products. Its number is JSMPA Yao Sheng Gao Zhi〔2024〕No. 278. It was issued by the Jiangsu Medical Products Administration on 14 September 2024. The applicable standard is Good Manufacturing Practice for Drugs (2010 Revision) and its relevant appendices. The supplied record gives the market as CN, EU and other markets.

The scope is written in manufacturing-line language. That is normal for a GMP inspection notice, but it is not the same as a product specification. References such as F&P and S Line or N Line identify the finishing and packing or production-line context described in the certificate. They help a buyer or auditor map the certificate to a site, but they do not state assay, impurity limits, particle size, packaging size or commercial terms.

Certificate elementSupplied detail
Formal titleNotice of GMP Compliance Inspection for Pharmaceutical Products
Certificate numberJSMPA Yao Sheng Gao Zhi〔2024〕No. 278
Issuing authorityJiangsu Medical Products Administration
Issue date14 September 2024
Applicable standardGood Manufacturing Practice for Drugs (2010 Revision) and its relevant appendices
Stated marketCN, EU and other markets
Listed API scopeAmlodipine Besylate API (F&P, S Line); Felodipine API (F&P, S Line); Propafenone HCl API (F&P, N Line); Methoxyphenamine HCl API (F&P, S Line); Levamlodipine Besylate API with synthesis and F&P location references

Which APIs are inside the scope

The shortest accurate answer is that Certificate No. 278 covers the API products named in its scope text. For the four products most relevant to the buyer question, the certificate lists Amlodipine Besylate, Felodipine, Propafenone Hydrochloride and Levamlodipine Besylate. The certificate text also lists Methoxyphenamine HCl API. A buyer should read the exact line references rather than assume that every product in a supplier’s portfolio is covered.

API named in Certificate No. 278Scope reference in the supplied certificate text
Amlodipine Besylate APIF&P, S Line
Felodipine APIF&P, S Line
Propafenone HCl APIF&P, N Line
Methoxyphenamine HCl APIF&P, S Line
Levamlodipine Besylate APISynthesis Area (1F, N Zone, Bldg.10; 1F,2F, S Zone, Bldg.10); F&P N Line, Bldg.7

Amlodipine Besylate

Amlodipine Besylate is the most heavily documented product in the supplied record. Certificate No. 278 lists Amlodipine Besylate API under F&P, S Line. A separate notice, No. 271, also covers Amlodipine Besylate API and describes synthesis at 1F, N Zone, Bldg.10; 1/2/3F, S Zone, Bldg.10; and F&P at N Line, Bldg.7. The overlap matters because No. 278 is not the only Jiangsu document an Amlodipine buyer may see. The product unit adds product-level data: CAS No. 111470-99-6, assay 98.0% to 102.0%, USP/EP standard, melting point 197°C to 201°C, 25 kg per drum packing, and MOQ 1 kg. Those are product specifications, not certificate scope items.

Felodipine

Felodipine API is listed under F&P, S Line. The supplied product unit gives CAS No. 72509-76-3, an assay of 98.0% to 101.0% on dried basis, compliance with USP/EP/BP monographs, impurity control stated to meet international pharmacopoeia standards, and consistent batch-to-batch performance as a supplier statement. Certificate No. 278 confirms that the product and line fall within the inspection scope; it does not set those assay or impurity values.

Propafenone Hydrochloride

Propafenone HCl API is listed under F&P, N Line. The supplied product record adds NMPA registration, Chinese GMP compliance, EU and PMDA audit history, ICH Q7 alignment, EP/USP/CP monograph compliance, COPP availability, a full CTD documentation package, impurity specifications, and customization such as particle size and micronization service. Separately, Propafenone Hydrochloride has EDQM Certificate of Suitability CEP 2023-038 - Rev 00, issued on 18 February 2025 for the EU/EEA market. That CEP states compliance with European Pharmacopoeia monograph No. 2103, an 18-month re-test period, no human or animal derived materials, and no intentionally added ICH Q3D elemental impurities. The CEP and Certificate No. 278 are distinct documents.

Levamlodipine Besylate

Levamlodipine Besylate API is listed with a more detailed site reference: Synthesis Area at 1F, N Zone, Bldg.10; 1F,2F, S Zone, Bldg.10; and F&P N Line, Bldg.7. The supplied product unit gives CAS No. 103129-82-4, molecular formula C₂₀H₂₅ClN₂O₅·C₆H₆O₃, assay 98.0% to 102.0% on dried basis, storage protected from light, sealed and in a cool dry place, and tight control of single and total impurities. The certificate scope confirms the site and line listing; it does not state those product-specific limits.

Methoxyphenamine HCl and the scope boundary

The certificate text also lists Methoxyphenamine HCl API under F&P, S Line. The supplied record does not include a standalone product specification for that API, so this article does not assign one. The procedural point is simple: if a buyer is sourcing Methoxyphenamine HCl, the certificate text should be read directly rather than assumed from a four-product summary.

By contrast, Tamsulosin Hydrochloride is not listed in the Certificate No. 278 scope text provided. The company record describes separate evidence for Tamsulosin Hydrochloride, including an FDA on-site inspection in 2018, a registration on-site verification and GMP compliance inspection in 2022, and a GMP compliance inspection in 2024. Those are different evidence points. A buyer should not use Certificate No. 278 as the qualification document for Tamsulosin Hydrochloride.

No. 278, No. 271 and JS250256: a document map

Certificate No. 278 often appears in a folder alongside other Jiangsu and EU documents. The buyer’s task is not to decide which certificate sounds strongest. The task is to map each document to the product, market and question it actually answers. The table below separates the main documents in the supplied record.

DocumentIssuer and dateProduct scopeMarket roleWhat it establishes
Certificate No. 278Jiangsu Medical Products Administration; 14 September 2024Amlodipine Besylate, Felodipine, Propafenone HCl, Levamlodipine Besylate and Methoxyphenamine HCl as listedCN, EU and other marketsGMP compliance inspection notice for the listed products and line references; not a batch release record and not a CEP
Notice No. 271Jiangsu Medical Products Administration; 14 September 2024Amlodipine Besylate API onlyCN, EU and other marketsAmlodipine-specific notice; the supplied text states it does not constitute an EU GMP certificate and is not a CEP certificate
JS250256Jiangsu Medical Products Administration; issued 20 October 2025, valid until 19 October 2028Amlodipine BesylateEUWritten confirmation for active substances exported to the EU; states chemical synthesis, compliance with EU GMP and WHO/ICH Q7, and regular regulatory inspections
FIMEA/2023/006159Finnish Medicines Agency; 18 April 2024Amlodipine BesylateEUEU GMP certificate covering manufacture of the active substance by chemical synthesis, including intermediate manufacturing, crude API production, salt formation, crystallisation, purification, finishing, packaging and quality control testing
R1-CEP 2008-074 - Rev 01EDQM; 3 March 2022Amlodipine BesylateEuropeCEP confirming quality compliance with European Pharmacopoeia monograph No. 1491; 36-month re-test period; no intentionally added ICH Q3D elemental impurities; Ruiming listed as a production site
CEP 2023-038 - Rev 00EDQM; 18 February 2025Propafenone HydrochlorideEU/EEACEP for European Pharmacopoeia monograph No. 2103; 18-month re-test period; no human or animal derived materials; no intentionally added ICH Q3D elemental impurities

The practical reading is document-specific. Certificate No. 278 answers a site-and-product scope question. Notice No. 271 answers a narrower Amlodipine scope question and carries an explicit limit: it is not an EU GMP certificate and not a CEP. JS250256 answers a different EU export-confirmation question for Amlodipine and has a stated validity until 19 October 2028. The FIMEA certificate and the EDQM CEPs answer EU GMP and pharmacopoeial suitability questions. A buyer who files only one of these documents may still have an evidence gap.

What the certificate does not establish

Certificate scope confirms qualification of the site for the listed products and line references. It does not confirm the assay, impurity profile, particle size, packaging configuration, MOQ, lead time or commercial supply commitment for a given batch. Those points sit in batch-specific quality documents and purchasing terms. The distinction is important because a certificate can be current while a batch is not released, and a batch can meet a COA while a commercial term remains unresolved.

Product units in the supplied record illustrate the gap. Amlodipine Besylate is listed with an assay of 98.0% to 102.0%, USP/EP standard, strict impurity control and 25 kg per drum packing. Felodipine is listed with an assay of 98.0% to 101.0% and USP/EP/BP compliance. Levamlodipine Besylate is listed with an assay of 98.0% to 102.0%, a defined molecular formula and storage conditions protected from light, sealed and cool dry. Propafenone Hydrochloride has a separate CEP scope that states an 18-month re-test period and specific elemental-impurity and material-origin statements. None of those values is written into the Certificate No. 278 scope text.

For that reason, a buyer should request the current certificate copy, the product-specific COA for the intended batch, the impurity profile, analytical methods, packaging specification and the supply terms that apply to the intended market. These are quality-document and procurement checks, not certificate substitutions.

Drying and packaging workshop for pharmaceutical API finishing
Drying and packaging workshop. Certificate scope covers listed products and lines; batch specifications and packaging details are confirmed separately.

How EU buyers can use the certificate in practice

For an Amlodipine Besylate EU project, the document set is layered. Certificate No. 278 covers the Jiangsu inspection scope. Notice No. 271 covers the Amlodipine-specific notice and states its own limits. JS250256 is the EU written confirmation valid until 19 October 2028. FIMEA/2023/006159 is the EU GMP certificate for Amlodipine Besylate active substance. R1-CEP 2008-074 - Rev 01 is the EDQM suitability certificate for European Pharmacopoeia monograph No. 1491. The buyer should check that the product name, CAS number, site or line reference and market match on each document.

For Felodipine, the supplied record provides Certificate No. 278 scope and product-level data, but it does not provide an EDQM CEP for Felodipine in this document set. A buyer should not infer a CEP from Certificate No. 278. For Propafenone Hydrochloride, Certificate No. 278 covers the Jiangsu scope listing, while CEP 2023-038 - Rev 00 covers the EDQM suitability record for European Pharmacopoeia monograph No. 2103. For Levamlodipine Besylate, Certificate No. 278 is the scope document in the supplied record; a separate CEP or EU GMP certificate for that product does not appear in the supplied set and should not be assumed.

This layered reading also affects supplier evaluation. A buyer comparing API suppliers can use Certificate No. 278 to verify that a named product and line were within a Jiangsu GMP inspection scope. The same buyer still needs to compare batch COAs, impurity methods, packaging, stability or re-test data, audit history and supply terms. A single certificate does not answer those questions.

Application scenarios: where the scope matters

The supplied application unit describes API supply for formulation development, EU registration submission and commercial production support. It lists working conditions of ambient temperature with protection from light and moisture, and a special requirement of compliance with EU GMP and EDQM CEP, impurity control meeting Ph. Eur., double PE bags inside fibre drums, protection from light and dry conditions, and full regulatory and audit documentation. It also names synthesis reactors, centrifuges, crystallizers, double cone rotary vacuum dryers, high-efficiency pulverizers, double cone blenders and GMP warehousing. These are operating, packaging and documentation requirements. They supplement Certificate No. 278; they do not turn the certificate into a batch specification.

For cardiovascular APIs, the product scope maps to concrete formulation uses. Amlodipine Besylate is used for antihypertensive tablet formulation and hypertension combination tablets. Felodipine is used for hypertension and stable angina pectoris finished drug formulation. Levamlodipine Besylate is used for antihypertensive tablets. Propafenone Hydrochloride is a cardiovascular API with registration, audit and customization documentation. Certificate No. 278 confirms that the listed API products and lines were within the inspection scope; the finished-dose manufacturer still needs batch-level quality data before commercial use.

One supplied customer case describes a French cardiovascular supply-chain partner using 800–1000 kg per year of Amlodipine Besylate for hypertension combination tablet manufacturing over three years. The reported result is batch quality consistently meeting EP requirements, a stable impurity profile, passing supplier quality assessment, and support for commercial formulation production. The same record cites CEP dossier availability, full batch traceability, flexible delivery schedule and an audit-ready quality system. That case illustrates why buyers combine certificate scope with batch and supply evidence. It does not make Certificate No. 278 a batch release document.

Finished pharmaceutical product packaging and storage context
Finished product packaging context. Packaging size, batch identity and storage conditions are confirmed through product and batch documents, not through certificate scope alone.

Procurement context, not a market forecast

The company profile states a 20% export ratio and the EU as a main market. It also states a 25,000 m² site, 149 employees, 27 R&D engineers, 180 tons annual output, two API production lines and one solid preparation line. Those are supplier-scale facts. They help a buyer understand the site context, but they do not expand the scope of Certificate No. 278 or prove capacity for a specific product or batch.

The broader procurement observation is limited to the supplied records: EU-bound API sourcing often requires a layered document set rather than a single certificate. Certificate No. 278, Notice No. 271, JS250256, the FIMEA certificate and the EDQM CEPs each answer a different question. This is a document-mapping point, not a claim about market size, growth rate or demand trend.

Future outlook: what to monitor

JS250256 has an explicit validity date of 19 October 2028. Certificate No. 278, Notice No. 271, FIMEA/2023/006159, R1-CEP 2008-074 - Rev 01 and CEP 2023-038 - Rev 00 do not have a specified expiry date in the supplied record. A missing expiry date is not a guarantee of perpetual validity. Buyers should verify the current status and revision of each document at the time of purchase, because certificates can be updated, replaced or read alongside newer inspection records.

Notice No. 271 and Certificate No. 278 share the same issue date, 14 September 2024. That shared date does not make them interchangeable. The product scope and stated limits differ. The same discipline applies to the EU documents: the FIMEA certificate and the EDQM CEPs are separate evidence, even when they concern the same Amlodipine Besylate product.

FAQ

What does Jiangsu GMP Certificate No. 278 cover?

Certificate No. 278 is a Notice of GMP Compliance Inspection for Pharmaceutical Products issued by the Jiangsu Medical Products Administration on 14 September 2024 under Good Manufacturing Practice for Drugs (2010 Revision) and its relevant appendices. The supplied scope lists Amlodipine Besylate API, Felodipine API, Propafenone HCl API, Methoxyphenamine HCl API and Levamlodipine Besylate API with specific line and area references. The record applies to CN, EU and other markets.

Is Certificate No. 278 the same as Notice No. 271?

No. Both are Jiangsu Medical Products Administration notices dated 14 September 2024, but Notice No. 271 covers Amlodipine Besylate API only and states that it does not constitute an EU GMP certificate and is not a CEP certificate. Certificate No. 278 has a broader product list. A buyer should use Notice No. 271 for the Amlodipine-specific notice and Certificate No. 278 for the broader scope, without treating them as interchangeable.

Does JS250256 replace Certificate No. 278 for EU buyers?

No. JS250256 is a written confirmation for active substances exported to the EU. It applies to Amlodipine Besylate, was issued on 20 October 2025 and is valid until 19 October 2028. It states that the product is manufactured by chemical synthesis, complies with EU GMP and WHO/ICH Q7, and is subject to regular regulatory inspections. Certificate No. 278 is a Jiangsu GMP compliance inspection notice with a different product list and document role.

Does Certificate No. 278 confirm batch specifications and impurity limits?

No. Certificate No. 278 confirms that the listed products and line references were within the GMP inspection scope. It does not state batch assay, impurity profile, analytical methods, packaging size or supply terms. The product units give separate product-level values, such as Amlodipine Besylate assay 98.0% to 102.0%, Felodipine assay 98.0% to 101.0% and Levamlodipine Besylate assay 98.0% to 102.0%. Those values still need to be confirmed on the relevant batch COA and quality documents.

Which document should an EU buyer check for Propafenone Hydrochloride?

Use Certificate No. 278 for the Jiangsu scope listing and CEP 2023-038 - Rev 00 for the EDQM suitability record. The Propafenone Hydrochloride CEP was issued on 18 February 2025 for the EU/EEA market and applies to European Pharmacopoeia monograph No. 2103. Its scope states an 18-month re-test period, no human or animal derived materials and no intentionally added ICH Q3D elemental impurities. Batch COA and supply terms remain separate checks.

What should buyers verify for packaging and supply conditions?

The certificate scope does not state packaging or commercial supply terms. The application unit describes solid API, sealed packaging, double PE bags inside fibre drums, protection from light and dry conditions, and batch-wise supply. The Amlodipine Besylate product unit lists 25 kg per drum packing. The capability unit states a 45–60 day lead time upon receipt of order and advance payment, a monthly capacity of 15 tons and no strict MOQ subject to negotiation. These are company-level or product-level statements, not certificate terms, so buyers should confirm the actual packaging specification, batch size, MOQ and delivery terms in the quality agreement or purchase order.

This article is a document-reading guide, not a regulatory determination or batch release statement. Certificate scope, product specifications and supply terms should be verified against the current issued documents and the intended batch at the time of purchase.

هل لديك أسئلة أو تحتاج إلى مزيد من التفاصيل؟

تواصل مع فريقنا للحصول على عرض أسعار مخصص أو استشارة فورية.

طلب عرض أسعار

املأ النموذج أدناه وسيتواصل معك فريقنا بعرض مقترح مخصص.

إرفاق صور أو ملفات أو مستندات.

سنرد خلال 24 ساعة (الاثنين إلى السبت).

محادثة واتساب مباشرة

تفضل الدردشة في الوقت الفعلي؟ راسلنا على واتساب للحصول على مساعدة فورية وإجابات سريعة.

  • احصل على عرض أسعار مخصص
  • مشاركة صور أو مستندات
  • ناقش احتياجاتك مباشرة
تحدث معنا على واتساب →

يresponder عادة خلال 5-30 دقيقة خلال ساعات العمل.

دعم: صور، فيديو، PDF